No medical condition will be investigated. To examine the effects of beta2-agonists on aerobic and anaerobic exercise performance.
Conditions
Interventions
Trade Name: Bricanyl
Product Name: Terbutaline
Product Code: R03AC03, R03CC03
Pharmaceutical Form: Inhalation powder
Pharmaceutical form of the placebo: Inhalation powder
Route of administration of th
Sponsors
Bispebjerg Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: -Sex: Male -Age: 18-40 -Physically active -Informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 9 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0
Exclusion criteria
Exclusion criteria: -Respiratory diseases -Smoker -Asthma -Heart disorders -Exercise-induced bronchoconstrition defined as a post-exercise drop in FEV1 > 10% following an incremental bicycle test to exhaustion. -Allergy towards the study medicine (Bricanyl, Ventolin, Lactose)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To examine the effects of beta2-agonists on aerobic and anaerobic exercise performance in healthy subjects.;Secondary Objective: To investigate potassium kinetics in skeletal muscle of healthy subjects.;Primary end point(s): Increased muscle strength, sprint ability and submaximal exercise performance.;Timepoint(s) of evaluation of this end point: 1,5 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Potassium kinetics;Timepoint(s) of evaluation of this end point: 1,5 years | — |
Countries
Denmark
Contacts
Public ContactBispebjerg Hospital
Bispebjerg Hospital Lungemedicinsk forskningesenhed
Outcome results
None listed